Why Certification of Packaging Materials is Critical

Packaging materials are in direct contact with the drug product throughout its shelf life. They can influence the product’s quality, safety, and efficacy. Regulatory agencies require manufacturers to demonstrate that these materials are suitable for use, have been properly tested, and are sourced from approved suppliers. Certification ensures that the packaging components:

• ✓ Meet predefined specifications and pharmacopeial standards (USP, Ph.Eur, JP)
• ✓ Are free from extractables, leachables, or other harmful contaminants
• ✓ Have consistent physical and chemical performance
• ✓ Are backed by complete documentation and change control records

Essential Certificates and Regulatory Documentation

The following documents must be obtained and maintained for each packaging component used in stability studies:

• Certificate of Analysis (CoA): Supplier-issued report confirming batch-wise testing results
• Certificate of Compliance (CoC): Declaration that the product complies with GMP, pharmacopeia, and regulatory expectations
• USP , , , Reports: Documentation of extractables, leachables, and physical properties
• DMF References: Drug Master File references (Type III) for container closure systems filed with the FDA
• Change Notification Policy: Supplier’s commitment to inform about composition or process changes

Key Regulatory Guidelines and Standards

When selecting and certifying packaging materials, manufacturers must refer to key global guidelines, including:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• ICH Q3C/Q3D: Impurities including residual solvents and elemental impurities
• 21 CFR Part 211 and 820: US GMP requirements for packaging
• EU GMP Annex 9: Use of primary and printed packaging materials
• WHO TRS Annexes on Stability and Packaging

Packaging Certification in Regulatory Dossiers

Packaging material certification data must be included in:

• CTD Module 3.2.P.7: Container closure system information
• Module 3.2.R: Regional-specific certifications and GMP declarations
• Risk Assessments: Related to packaging interactions and stability

Failure to provide complete documentation may result in deficiency letters, delayed approvals, or even rejections.

Case Example: EMA Query on Container Closure Declaration

During centralized review, the EMA requested additional data for a parenteral product. The sponsor had failed to submit extractables and leachables data for the rubber stopper. Despite having stability data, approval was delayed by 4 months until appropriate EMA expectations were met with certified reports and supporting risk assessments.

Supplier Qualification and Audit Expectations

Packaging suppliers play a pivotal role in ensuring regulatory compliance. Pharmaceutical companies must:

• ✔ Qualify suppliers through GMP audits and quality questionnaires
• ✔ Obtain CoA and CoC for each shipment or batch used
• ✔ Implement Quality Agreements covering responsibilities and notification clauses
• ✔ Periodically re-evaluate suppliers based on risk and performance

Auditors from regulatory agencies routinely inspect documentation related to supplier qualification, material traceability, and change management.

Testing and Verification of Certified Packaging Materials

Even when a CoA is provided, pharma companies must conduct their own verification testing to confirm compliance:

• Identification by FTIR or other spectroscopic techniques
• Physical inspection (dimensions, weight, torque, clarity)
• Extractables testing if new supplier or change in formulation
• Label and ink testing for migration or solvent compatibility
• Documentation of test results, review by QA

Checklist for Packaging Certification Compliance

• ☑ Have all packaging components undergone extractables and leachables testing?
• ☑ Is the packaging material certified for intended use (e.g., oral, parenteral)?
• ☑ Are all CoA and CoC records traceable and reviewed by QA?
• ☑ Has the supplier been GMP audited within the last 3 years?
• ☑ Are packaging specifications and certificates filed in the product dossier?

Cross-Linking Packaging and Stability Programs

Certifications must directly align with the packaging used in actual stability testing. Using non-certified or alternate packaging will compromise data integrity. As a best practice:

• Link packaging certificate ID with each stability batch record
• Include certificates in stability reports
• Flag packaging-related OOS or trends during stability trending reviews

More on packaging SOPs and documentation can be found at pharma SOPs.

Conclusion

Certifying packaging materials used in stability studies is a critical component of regulatory compliance. Through thorough supplier qualification, verification testing, documentation control, and inclusion in regulatory submissions, pharma manufacturers can safeguard product quality, avoid regulatory delays, and meet global standards. Certification isn’t just paperwork—it’s an assurance of integrity, consistency, and patient safety.

References:

• ICH Q1A(R2), Q3C, Q3D Guidelines
• USP Chapters <661.1>, <661.2>, <671>, <381>
• USFDA Guidance on Container Closure Systems
• EU GMP Annex 9: Packaging Materials
• WHO TRS 1010 Annex 10 – Stability Guidelines

Why Labeling and Packaging Alignment Matters in Stability Submissions

Stability testing supports product shelf life, storage conditions, and labeling claims. If packaging and labeling used during studies don’t match the intended commercial presentation, regulators may question data relevance. Additionally:

• ⚠️ ICH guidelines specify packaging and labeling details for each zone
• ⚠️ Label discrepancies can delay product launches
• ⚠️ Stability claims must be consistent with temperature and expiry labeling

Therefore, it is critical to plan a harmonized labeling strategy from the start of the stability study protocol.

Step 1: Understand Regional Requirements and Labeling Norms

While ICH provides a foundational guideline, each region may impose additional labeling rules:

• 📝 EMA: Requires language-specific labels, expiry dating formats (e.g., MM/YYYY), and pictograms for cold-chain products
• 📝 USFDA: Mandates statement formats like “Store at 20°C to 25°C (68°F to 77°F)” and child-resistant packaging labels
• 📝 ASEAN: Emphasizes humidity protection statements and local language inclusion on secondary packaging

Document these regional nuances early using a master reference table for easy comparison.

Step 2: Choose Globally Acceptable Packaging Configurations

Packaging types directly impact stability. Use options that are globally accepted:

• 📦 Blisters: PVC/PVDC/Alu for better barrier protection in tropical climates
• 📦 Bottles: HDPE with induction sealing and desiccant for humidity-sensitive drugs
• 📦 Sachets: Laminated aluminum foil suitable for powders and granules

Ensure your chosen packaging is compatible with all climate zones applicable to your submission markets. Refer to USFDA guidelines for primary packaging materials.

Step 3: Align Label Content With Stability Protocol Claims

Your stability label must reflect the conditions being tested. Key label elements include:

• ✅ Storage conditions (e.g., “Store below 30°C”, “Protect from light”)
• ✅ Expiry date calculation format (use of month/year or DD/MM/YYYY)
• ✅ Batch number matching the stability study record
• ✅ Sampling time points and analytical test references

Discrepancies between the label and what’s described in the GMP guidelines can result in warning letters or audit observations.

Step 4: Manage Multilingual Labeling and Artwork Versions

For regions like the EU and ASEAN, labeling must appear in the official language(s) of the country. This affects font size, layout, and even packaging dimensions.

• 💬 Consider using booklet labels for multilingual content
• 💬 Implement a centralized label artwork management system
• 💬 Validate print quality, permanence, and readability across language versions

This ensures that stability samples used for regional studies bear compliant and auditable labeling for each authority.

Step 5: Standardize Label Templates and Approvals

To maintain consistency across global sites, develop standardized label templates that include:

• ✅ Predefined zones for product name, batch number, and expiry
• ✅ Pre-approved storage condition statements for ICH zones I–IV
• ✅ Built-in controls for label versioning and revision history

Centralized label approval by global Regulatory Affairs and QA ensures compliance and audit traceability. Digital approval workflows using Document Management Systems (DMS) are preferred.

Step 6: Integrate Container Closure Labeling Requirements

Labeling isn’t just about the outer packaging. Primary containers—blisters, vials, ampoules—must also carry critical data such as:

• 🔑 Unique ID or batch code
• 🔑 Strength and dosage form
• 🔑 Storage instructions if not visible on secondary label

Ensure these details are printed using permanent inks or laser etching for compliance with EMA and WHO standards.

Step 7: Address Labeling During Product Lifecycle Changes

Regulatory authorities expect updated labeling during post-approval changes (e.g., shelf-life extensions). Your SOP should define:

• 📅 Version control of stability label templates
• 📅 Bridging strategies when switching from old to updated labels
• 📅 Retesting or re-labeling procedures for ongoing studies

Maintain audit trails of all label changes made during the product lifecycle, especially in long-term stability programs.

Step 8: Ensure Regulatory Submission Readiness

Authorities such as CDSCO and ICH members expect labeling alignment between clinical data, stability protocols, and product dossiers. When preparing Module 3 of the CTD:

• ✅ Include scanned samples of stability labels used
• ✅ Provide justification for any regional label adaptations
• ✅ Reference packaging material specs in Module 3.2.P.7

This ensures no last-minute regulatory delays due to incomplete or inconsistent labeling documentation.

Conclusion: Make Harmonized Labeling a Competitive Advantage

Pharma companies aiming for simultaneous multi-country filings must treat labeling and packaging as strategic pillars, not afterthoughts. By planning harmonized label content, packaging formats, and language strategies upfront, you can avoid costly delays, reduce risk of queries, and speed up your global market entry.

Build alignment into your product lifecycle, from development batches to post-approval changes. In today’s competitive market, effective labeling isn’t just a compliance checkbox—it’s a gateway to trust, access, and global success.